StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Sarepta Therapeutics (SRPT) Shorts Squeezed After Eteplirsen Receives FDA Approval
September 19, 2016 11:27 AM
Sarepta Therapeutics (NASDAQ: SRPT) shorts were pressured after the FDA approved its DMD ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Short Sales
Trader Talk
Next Articles
Sarepta (SRPT) Wins Key PTO Decision on Composition of Matter Patents - Oppenheimer
September 20, 2016 1:18 PM
Sarepta Therapeutic (SRPT) PT Raised to $66 at Wedbush
September 20, 2016 7:21 AM
RBC Capital Upgrades Sarepta (SRPT) to Outperform; Becomes Attractive M&A Target
September 19, 2016 1:52 PM
Sarepta Therapeutic (SRPT) PT Raised to $81 at Needham & Company
September 19, 2016 1:37 PM
Leerink Partners Upgrades Sarepta Therapeutic (SRPT) to Market Perform
September 19, 2016 1:29 PM
Sarepta (SRPT) PT Raised to $76 at Oppenheimer Amid Eteplirsen Approval
September 19, 2016 1:08 PM
Sarepta Therapeutics (SRPT) Pushes to Highs Following FDA Approval; +90%
September 19, 2016 11:21 AM
FDA Approves Sarepta Therapeutics' (SRPT) Eteplirsen
September 19, 2016 9:52 AM
Sarepta Therapeutics (SRPT) Granted FDA Accelerated Approval for Eteplirsen
September 19, 2016 9:51 AM
